2-(3,5-difluoroanilino)-1,4-naphthoquinone | 1276184-20-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(3,5-difluoroanilino)-1,4-naphthoquinone
• 英文别名: 2-((3,5-difluorophenyl)amino)naphthalene-1,4-dione；2-(3,5-Difluoroanilino)naphthalene-1,4-dione；2-(3,5-difluoroanilino)naphthalene-1,4-dione
• CAS: 1276184-20-3
• 化学式: C₁₆H₉F₂NO₂
• 分子量: 285.25
• InChiKey: RFZFJSSOVGAKMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,5-二氟苯胺 在 potassium carbonate 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.17h， 生成 2-(3,5-difluoroanilino)-1,4-naphthoquinone
  参考文献：
  名称：

  Novel 2-Amino-1,4-Naphthoquinone Derivatives Induce A549 Cell Death through Autophagy

  摘要：

  合成了一系列可用作抗癌剂的 1,4-萘醌衍生物，并通过 X 射线衍射证实了化合物 5a 的晶体结构。化合物 5i 对 A549 细胞株具有显著的细胞毒性，IC50 为 6.15 μM。令人惊讶的是，在接下来的初步生物学实验中，我们发现化合物 5i 通过促进表皮生长因子受体（EGFR）的循环和信号转导，诱导了 A549 细胞的自噬，从而激活了 EGFR 信号通路。分子对接还确定了化合物 5i 与表皮生长因子受体酪氨酸激酶（PDB ID：1M17）的潜在结合模式。我们的研究为进一步研究和开发新型强效抗癌药物铺平了道路。

  DOI：

  10.3390/molecules28083289

文献信息

• Synthesis, spectral and electrochemical characterization of novel 2-(fluoroanilino)-1,4-naphthoquinones
  作者：Elisa Leyva、Lluvia I. López、Silvia E. Loredo-Carrillo、Margarita Rodríguez-Kessler、Antonio Montes-Rojas

  DOI：10.1016/j.jfluchem.2010.12.001

  日期：2011.2

  The preparation of novel 2-(fluoroanilino)-1,4-naphthoquinones is presented. It takes place under mild conditions by reacting the corresponding fluoroaniline and 1,4-naphthoquinone in the presence of a Lewis acid catalyst with strong oxidation properties such as CeCl3·7H2O. This preparation was also investigated under microwave irradiation. All 1,4-naphthoquinone derivatives were characterized by UV–Vis

  介绍了新型2-（氟苯胺基）-1,4-萘醌的制备。它是在温和的条件下，通过使相应的氟苯胺和1,4-萘醌在具有强氧化性能的路易斯酸催化剂（例如CeCl 3 ·7H 2 O）存在下反应来进行的。该制备方法也在微波辐射下进行了研究。所有1，4-萘醌衍生物均通过UV-Vis，IR，1 H和19 F NMR，MS和循环伏安法进行表征，以研究含氟取代基对其电子性能的影响。
• Compositions and methods for treatment of prostate carcinoma
  申请人：Pellficure Pharmaceuticals, Inc.

  公开号：US10093620B2

  公开（公告）日：2018-10-09

  Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

  本文公开了1,4-萘醌类似物、包括一种或多种此类1,4-萘醌类似物的药物组合物，以及用此类1,4-萘醌类似物治疗和/或改善与癌症（如前列腺癌）相关的疾病和/或病症的方法。还包括组合疗法，其中向患有癌症等疾病的受试者提供本文公开的 1,4-萘醌类似物和激素治疗剂。
• COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA
  申请人：Pellficure Pharmaceuticals, Inc.

  公开号：US20170283374A1

  公开（公告）日：2017-10-05

  Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.